Investigational drug · Phase 3
Elecoglipron
Not approved by FDA. In 9 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Type 2 Diabetes Mellitus, Obesity, Overweight.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
9
9 still active
All registered trials
11
Any phase or sponsor naming "Elecoglipron"
First trial start
2026
Jun 29, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Elecoglipron", any sponsor or status.
Conditions studied
As listed on its trial records.
- Type 2 Diabetes Mellitus
- Obesity
- Overweight
- Type 2 Diabetes With Chronic Kidney Disease
- Weight Management
- Chronic Kidney Disease
- Heart Failure With Preserved Ejection Fraction (HFpEF)
- Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
Approved drugs for the same conditions: Type 2 diabetes · Obesity and weight management · Heart failure · Chronic kidney disease · Cardiovascular and metabolic · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "Elecoglipron" as an intervention, largest first.
- A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.Pivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07753993 · 7,000 participants (planned) · Start Aug 21, 2026 · Primary completion Oct 4, 2030
Drug: Elecoglipron; Placebo · For: Chronic Kidney Disease
Sites: Huntsville, Alabama; Montgomery, Alabama; Sheffield, Alabama · 715 sites in all
- A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEFPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07761117 · 6,950 participants (planned) · Start Aug 24, 2026 · Primary completion Sep 3, 2029
Drug: Elecoglipron; Placebo · For: Heart Failure With Preserved Ejection Fraction (HFpEF); Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
Sites: Fairhope, Alabama; Anchorage, Alaska; Gilbert, Arizona · 679 sites in all
- A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DMPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07667803 · 4,500 participants (planned) · Start Jun 29, 2026 · Primary completion Jul 31, 2028
Drug: Elecoglipron; Placebo · For: Weight Management
Sites: Birmingham, Alabama; Dothan, Alabama; Chandler, Arizona · 325 sites in all
- A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes MellitusPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07662109 · 2,000 participants (planned) · Start Jul 6, 2026 · Primary completion Jul 5, 2028
Drug: Elecoglipron; Dapagliflozin and 2 more · For: Type 2 Diabetes Mellitus
Sites: Huntsville, Alabama; Mobile, Alabama; Sheffield, Alabama · 303 sites in all
- A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes MellitusPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07662213 · 1,200 participants (planned) · Start Jul 6, 2026 · Primary completion May 23, 2028
Drug: Elecoglipron; Semaglutide · For: Type 2 Diabetes Mellitus
Sites: Birmingham, Alabama; Mesa, Arizona; Phoenix, Arizona · 210 sites in all
- A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background DapagliflozinPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07662135 · 900 participants (planned) · Start Jul 6, 2026 · Primary completion Jul 13, 2028
Drug: Elecoglipron; Placebo · For: Type 2 Diabetes Mellitus; Type 2 Diabetes With Chronic Kidney Disease
Sites: Sun City, Arizona; Surprise, Arizona; Concord, California · 186 sites in all
- A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes MellitusPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07662044 · 800 participants (planned) · Start Jul 6, 2026 · Primary completion Jul 14, 2028
Drug: Elecoglipron; Dapagliflozin and 2 more · For: Type 2 Diabetes Mellitus
Sites: Birmingham, Alabama; Daphne, Alabama; Lomita, California · 149 sites in all
- A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background InsulinPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07664553 · 600 participants (planned) · Start Jul 8, 2026 · Primary completion May 23, 2028
Drug: Elecoglipron; Placebo · For: Type 2 Diabetes Mellitus
Sites: Little Rock, Arkansas; Sacramento, California; Aurora, Colorado · 132 sites in all
- A Study to Investigate the Efficacy and Safety of Elecoglipron in Asian Participants With Obesity or Overweight With or Without Type 2 Diabetes MellitusPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07775404 · 351 participants (planned) · Start Aug 21, 2026 · Primary completion Apr 6, 2028
Drug: Elecoglipron; Placebo · For: Obesity; Overweight
Sites: Baotou, China; Beijing, China; Changde, China · 49 sites in all
- A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy ParticipantsPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07723833 · 152 participants (planned) · Start Jul 27, 2026 · Primary completion Nov 18, 2026
Drug: Elecoglipron Reference Formulation Dose A; Elecoglipron Test formulation 1 Dose A and 4 more · For: Healthy Participants
Sites: Glendale, California; Brooklyn, Maryland
Newest research
PubMed records naming it or its code names, newest first.
- Interpreting meal-independent dosing in a fixed-sequence pharmacokinetic study of elecoglipron.
Cai X, Kong M · Br J Clin Pharmacol 2026
- Phase 1, open-label, randomized study of the elecoglipron pharmacokinetic profile in healthy participants under fed and fasted conditions.
Xu J, Haggag A, Butcher L, et al. · Br J Clin Pharmacol 2026
- Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with type 2 diabetes (SOLSTICE): a multicentre, phase 2b, randomised, placebo-controlled trial.
Aroda VR, Davies MJ, Maaske J, et al. · Lancet 2026
- Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with obesity or overweight (VISTA): a multicentre, phase 2, randomised, placebo-controlled clinical trial.
Davies MJ, Aroda VR, Rosenstock J, et al. · Lancet 2026
Also in development for Type 2 Diabetes Mellitus
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- LenbelintideAZD6234Phase 39 trials
AstraZeneca · Obesity or Overweight, Obesity, Overweight
- ASC30 A1ASC30Phase 35 trials
Ascletis Pharma (China) Co., Limited · Chronic Weight Management, Obesity, Overweight
- SHR-3167Phase 35 trials
Jiangsu HengRui Medicine Co., Ltd. · Diabetes Mellitus, Type 2, Type 2 Diabetes, Type 2 Diabetes Mellitus
- HTD1801Berberine UrsodeoxycholatePhase 34 trials
Shenzhen HighTide Biopharmaceutical Ltd. · T2DM (Type 2 Diabetes Mellitus), Nonalcoholic Steatohepatitis (NASH), Type 2 Diabetes
- DA-302168SPhase 33 trials
Chendu DIAO Pharmaceutical Group CO., LTD. · Overweight and Obesity, Type 2 Diabetes Mellitus
- TG103Phase 33 trials
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. · Type 2 Diabetes Mellitus, Overweight or Obesity
- Exendin-4 Fc fusion proteinJY09Phase 32 trials
Beijing Dongfang Biotech Co., Ltd. · Type2 Diabetes Mellitus, Type 2 Diabetes Mellitus
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.